Champignon Manufacturers to Restate Financial Statements and MD&A has Geared up CSE Listing Assertion

VANCOUVER, BC, Feb. 17, 2021 /PRNewswire/ – Champignon Manufacturers Inc. (the “Firm”), (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), announced that as a outcome of a evaluate by the British Columbia Securities Fee (the “Commission”), the Organization has determined to withdraw and refile its condensed interim consolidated financial statements and management’s dialogue & evaluation (“MD&A”) for the 3 and six month intervals ended March 31, 2020 (the “Primary Financial Statements and MD&A”).

(CNW Group/Champignon Brands Inc.)

(CNW Team/Champignon Brands Inc.)

For the three and 6 month durations ended March 31, 2020, the Firm previously identified intangible assets in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. (the “Acquisitions”) that aggregated approximately $12 million. Subsequent to the issuance of the Original Monetary Statements and MD&A, management decided that the money statements essential to be restated to proper the accounting for the Acquisitions as the property do not meet the definition of intangible belongings for the uses of worldwide economic reporting standards and as outcome will be recorded as transaction expenditures in the Firm’s statement of decline and detailed loss. The restated condensed interim consolidated money statements and MD&A will replicate this alter in the accounting remedy of the property obtained in these acquisitions. The effect of the restatements does not influence the Company’s cash position.

In addition, it was established that a shareholder and contracted consultant (the Marketing consultant”) of the Company was a similar celebration with respect to the Acquisitions. As a consequence, the restated condensed interim consolidated fiscal statements and MD&A will include further disclosure particulars with regard to relevant social gathering transactions involving the Marketing consultant.

The Business also expects to concurrently file condensed interim consolidated monetary statements and related MD&A’s for the 3 months ended June 30, 2020 and for the 6 months ended September 30, 2020 (the “September Interim Monetary Statements and MD&A”). The September Interim Monetary Statements and MD&A will reflect the acquisition of Altmed Capital Corp. (“Altmed”) on April 30, 2020 (the “Transaction”). The Transaction constituted a Reverse Takeover Transaction (“RTO”) of Champignon by Altmed. As a outcome, the fiscal year conclusion of the Business for accounting and reporting applications subsequent to April 30, 2020 will be Altmed’s fiscal yr close of March 31.

The Organization has submitted drafts of the restated condensed interim consolidated money statements and management’s discussion & analysis (“MD&A”) for the three and six thirty day period durations finished March 31, 2020 (the “Restated Money Statements and MD&A”) and the September Financial Statements and MD&A to the Commission for assessment. Until eventually the Restated Financial Statements and MD&A are submitted, the Primary Monetary Statements and MD&A ought to not be relied on and should be regarded to have been withdrawn.

CSE Listing Status/Stop Trade Orders

The Organization has also currently filed a draft of a new Listing Assertion with the Commission and the Canadian Securities Exchange (“CSE”) for critique. The Listing Assertion displays the acquisition of Altmed and the RTO. The Organization was essential to file the new Listing Statement as a issue to the lifting of the current cease trade orders issued by the Commission and prior to the Firm’s Typical Shares being reinstated for buying and selling on the CSE. The existing stop trade orders, issued on August 26, 2020 and October 27, 2020, effectively give that the Business must file:

  • a revised content change report reflecting the accounting remedy for the Altmed transaction

  • interim fiscal statements for the period of time finished June 30, 2020,

  • interim MD&A to June 30, 2020, and

  • certification of interim filings for the period finished June 30,2020.

Drafts of these filings have been submitted to the Commission for critique. The Company is doing the job diligently with the Commission and the CSE to make certain that the revocation of the existing stop trade orders in opposition to the Enterprise and the filing of the new Listing Assertion occur as quickly as probable. Having said that, there can be no assurance as to when (if ever) the Restated Monetary Statements and MD&A and the September Monetary Statements and MD&A will be filed. Equally, there can be no assurance as to when (if at any time) the existing cease trade orders will be lifted, the new Listing Statement will be done and buying and selling in the Company’s Typical Shares will be reinstated on the CSE.

Champignon Manufacturers Inc. ( is a study-pushed organization specializing in breakthrough ketamine procedure for depression and other psychological health situations. The Business operates carefully with subsidiaries including AltMed Capital Corp. (“AltMed”). The Canadian Immediate Cure Heart of Excellence is wholly owned by AltMed.


Dr. Roger McIntyre
Dr. Roger McIntyre
Chairman & CEO

Phone crisis healthcare expert services promptly if you feel you are experiencing a professional medical unexpected emergency. Do not count on communication by the Champignon Makes internet site of the e-mail/phone numbers previously mentioned for urgent medical demands. Champignon Models Inc. does not provide clinical suggestions. If you have any precise professional medical questions or are in search of information, you should seek the advice of with your wellbeing treatment supplier.

The CSE has not reviewed and does not take accountability for the precision or adequacy of this launch.

Ahead-seeking Data Cautionary Statement

This information launch includes ahead-seeking statements inside of the this means of relevant securities rules. All statements that are not historical points, long term estimates, programs, applications, forecasts, projections, aims, assumptions, expectations, or beliefs of long run performance are “ahead-wanting statements.” Forward-seeking statements incorporate statements with respect to the submitting of the Restated Economical Statements and MD&A, the filing of the September Financial Statements and MD&A, the completion of a new Listing Assertion with the CSE, the lifting of the current cease trade orders by the Commission and the reinstatement of investing in the Company’s Common Shares on the CSE. Ahead-searching statements can be determined by the use of words and phrases this sort of as “strategies”, “expects” or “does not expect”, “is predicted”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of these types of text and phrases or statements that specified actions, activities or success “could”, “could”, “would”, “may” or “will” be taken, come about or be achieved. These types of ahead- on the lookout statements entail recognised and unknown risks, uncertainties and other factors that may trigger precise outcomes, situations, or developments to be materially diverse from any future outcomes, activities or developments expressed or implied by this kind of forward-on the lookout statements. These kinds of risks and uncertainties include things like, among the others, the Company’s specifications for supplemental funding, and the result of capital market place circumstances and other components on cash availability, the Firm’s confined functioning historical past and absence of historical earnings levels of competition failure of solutions to give the predicted overall health advantages unanticipated aspect consequences dependence on getting and retaining regulatory approvals, such as attaining and renewing federal, provincial, state, municipal, neighborhood or other licenses developments and improvements in legal guidelines and laws, which include greater regulation of the Firm’s industries and the capital marketplaces financial and economical disorders volatility in the cash markets engaging in routines that could be later decided to be illegal beneath domestic or intercontinental regulations failure to attain the necessary shareholder, government or regulatory approvals, like that of the CSE and failure to keep, secure and keep vital personnel and strategic partnerships including but not minimal to executives, scientists, clinicians, shoppers and suppliers. These things ought to be deemed carefully, and viewers are cautioned not to place undue reliance on these kinds of forward-looking statements. Though the Business has tried to recognize important risk elements that could induce precise steps, activities or outcomes to vary materially from those people explained in ahead-hunting statements, there may be other threat factors that bring about steps, gatherings or effects to vary from all those expected, approximated or meant. More information and facts determining dangers and uncertainties that could have an impact on monetary effects is contained in the Firm’s filings with Canadian securities regulators, which are out there at There can be no assurance that ahead-on the lookout statements will establish to be exact, as genuine success and long term activities could vary materially from those people anticipated in ahead-seeking statements. The Business has no obligation to update any forward-seeking assertion, even if new info will become out there.


Look at first written content to down load multimedia: names-to-restate-financial-statements-and-mda-has-well prepared-cse-listing-assertion-301230292.html

Source Champignon Manufacturers Inc.